Review
The nephropathy of systemic lupus erythematosus
Affiliations
- PMID: 2979809
Item in Clipboard
Review
The nephropathy of systemic lupus erythematosus
In Vivo.
1988 Jan-Feb.
Abstract
Lupus nephritis may be considered the prototypic autoimmune disease which is initiated by immune complex deposition. Several patterns of localization of immunoreactants are observed in lupus nephritis, but few data are available to elucidate the corresponding immunopathogenetic mechanisms. Corticosteroids form the mainstay of therapy for lupus nephritis, provided that they achieve a prompt clinical remission which can be sustained with alternate day therapy. Cyclophosphamide may have fewer risks than extended high-dose prednisone and it has been shown to be more efficacious than corticosteroids in preventing end stage renal failure.
Similar articles
-
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461. Arthritis Rheum. 2002. PMID: 12209517 Clinical Trial.
-
Immunosuppressive treatment of the glomerulonephritis of systemic lupus.Clin Nephrol. 1995 Dec;44(6):367-75. Clin Nephrol. 1995. PMID: 8719548
-
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.Arthritis Rheum. 2004 Dec;50(12):3934-40. doi: 10.1002/art.20666. Arthritis Rheum. 2004. PMID: 15593207 Clinical Trial.
-
Lupus nephritis.Semin Nephrol. 2006 Mar;26(2):95-104. doi: 10.1016/j.semnephrol.2005.09.002. Semin Nephrol. 2006. PMID: 16530602 Review.
-
Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?Nat Clin Pract Rheumatol. 2005 Nov;1(1):22-30. doi: 10.1038/ncprheum0016. Nat Clin Pract Rheumatol. 2005. PMID: 16932624 Review.